Armata Pharmaceuticals (Armata Pharmaceuticals) Market Cap : $99.77 Mil (As of Apr. 28, 2024)

View and export this data going back to 1994. Start your Free Trial

What is Armata Pharmaceuticals Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Armata Pharmaceuticals's share price for the quarter that ended in Dec. 2023 was $3.24. Armata Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 36.12 Mil. Therefore, Armata Pharmaceuticals's market cap for the quarter that ended in Dec. 2023 was $117.04 Mil.

Armata Pharmaceuticals's quarterly market cap increased from Jun. 2023 ($41.19 Mil) to Sep. 2023 ($108.37 Mil) and increased from Sep. 2023 ($108.37 Mil) to Dec. 2023 ($117.04 Mil).

Armata Pharmaceuticals's annual market cap declined from Dec. 2021 ($148.58 Mil) to Dec. 2022 ($44.82 Mil) but then increased from Dec. 2022 ($44.82 Mil) to Dec. 2023 ($117.04 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Armata Pharmaceuticals's Enterprise Value for Today is $206.61 Mil.

Armata Pharmaceuticals Market Cap Historical Data

The historical data trend for Armata Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Armata Pharmaceuticals Market Cap Chart

Armata Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Market Cap

Get a 7-Day Free Trial

32.25

55.78

148.58

44.82

117.04

Armata Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Market Cap	Get a 7-Day Free Trial															44.82	60.36	41.19	108.37	117.04

Competitive Comparison of Armata Pharmaceuticals's Market Cap

For the Biotechnology subindustry, Armata Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Armata Pharmaceuticals's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Armata Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where Armata Pharmaceuticals's Market Cap falls into.

Armata Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Armata Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )	=	Share Price (A: Dec. 2023 )	*	Shares Outstanding (EOP) (A: Dec. 2023 )
	=	$3.24	*	36.1229
	=	$117.04

Armata Pharmaceuticals's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )	=	Share Price (Q: Dec. 2023 )	*	Shares Outstanding (EOP) (Q: Dec. 2023 )
	=	$3.24	*	36.1229
	=	$117.04

Armata Pharmaceuticals (AMEX:ARMP) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Armata Pharmaceuticals Market Cap Related Terms

Thank you for viewing the detailed overview of Armata Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Armata Pharmaceuticals (Armata Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Armata Pharmaceuticals Inc (AMEX:ARMP) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

TG1M:Germany

Address

4503 Glencoe Avenue, Marina del Rey, CA, USA, 90292

Website

https://www.armatapharma.com

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Further, the company is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

Executives

Richard Rychlik	officer: Corporate Controller and PFO	5005 MCCONNELL AVENUE, LOS ANGELES CA 90066
Deborah Birx	director, officer: Chief Executive Officer	3300 LOWELL STREET NW, WASHINGTON DC 20008
Julianne Averill	officer: Chief Financial Officer	361 NEWBURY STREET, SUITE 500, BOSTON MA 02115
Erin Butler	officer: Vice President,Finance & Admin	4375 LOMA RIVIERA COURT, SAN DIEGO CA 92110
Theravance Inc	director, 10 percent owner	1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010
Jules Haimovitz	director	601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
Innoviva Strategic Opportunities Llc	director, 10 percent owner	1209 ORANGE STREET, WILMINGTON DE 19801
Robin Kramer	director	999 VANDERBILT BEACH ROAD, 3RD FLOOR, NAPLES FL 34109
Steven Robert Martin	officer: Chief Financial Officer	11011 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Kostas D Odysseas	director	660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarah J. Schlesinger	director	C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jeremy Curnock Cook	director	TARGETED GENETICS CORP, 1100 OLIVE WAY STE 100, SEATTLE WA 98101
Michael S Perry	director	C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Todd C. Peterson	director	C/O ARMATA PHARMACEUTICALS, INC., 4503 GLENCOE AVENUE, MARINA DEL REY CA 90292
H Stewart Parker	director